Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovato dual therapy study in adults with HIV and legacy HIV-associated brain injury
ISRCTN47418801Phase 4Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV), sponsored by Imperial College London. Primary endpoint: Undetectable cerebrospinal fluid HIV RNA after study intervention. Started Oct 2025; status: active, not recruiting.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN47418801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47418801.